IACTA Pharmaceuticals
27101 Puerta Real
Suite 240
Mission Viejo
California
92691
United States
Website: http://iactapharma.com/
About IACTA Pharmaceuticals
IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products. We’re dedicated to treating diseases, advancing technology and improving patient outcomes.Our lead investigational product, NM133, is a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye. Using licensed proprietary Molecular Envelope Technology (MET) from the research stage company Nanomerics, Ltd., this unique nanotechnology allows a hydrophobic drug to be encapsulated and delivered to the tissues of the eye with favorable tissue permeation.
We are developing this innovative drug as a new treatment option for patients with dry eye.
YEAR FOUNDED:
2016
LEADERSHIP:
Founder and CEO: Damon Burrows
7 articles about IACTA Pharmaceuticals
-
IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders
6/29/2022
IACTA Pharmaceuticals, Inc. ("IACTA"), an innovation leader in ophthalmic therapeutics, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Dr. Richard L. Abbott and Dr. Lixin Xie.
-
IACTA Pharmaceuticals to Present at Jefferies Healthcare Conference
6/1/2022
IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, today announced that Damon Burrows, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:30 a.m. ET.
-
IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology
12/15/2021
IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. (“TALLC”), a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, today announced that they are entering into a strategic collaboration and licensing agreement.
-
IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury
10/28/2021
IACTA Pharmaceuticals, Inc. today announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800
-
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
1/7/2021
- Ocular Pain, a $10+ billion global market, with significant unmet medical need - License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies
-
New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals' Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asia
7/28/2020
Agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited, a subsidiary of Lee's Pharmaceutical Holdings Limited, provides license to IC 265 and IC 270, novel first-in-class therapies being developed for dry eye and allergic conjunctivitis, respectively, in China, a major growth market, and Southeast Asia [28-July-2020] IRVINE, Calif. and HONG KONG , July
-
IACTA Pharma Release: Pharma Licenses NM133 From Nanomerics For Treatment Of Dry Eye
1/11/2017